The InCor researchers are excited to hear that the long-covid study will feature CBD (Cannabidiol, a substance derived from Cannabis) with sanitary registration from Anvisa (Agency for Sanitary Surveillance). “Now doctors and patients are even more confident. This also increases the credibility of the results,” says study coordinator Edimar Bocchi, who is a professor at the USP School of Medicine (University of São Paulo).
Anvisa’s requirements for granting registration for a product from Cannabis are the same as any drug sold at the pharmacy. The record attests, for example, that an analgesic will always have the same concentration and quality.
In long Covid’s research, InCor will use CBD 50 mg/ml from Farmacêutica Verdemed, which obtained registration last Friday, 27. But for the general public, the company says that the product will only reach Brazilian pharmacies in the second half of next year.
Verdemed’s CBD is the result of a partnership with the American publicly-held company Clever Leaves, with a laboratory and cultivation fields in Colombia. It has EUDRA Good Manufacturing Practice pharmaceutical certification. All these details, which in general lay people do not pay attention to, matter a lot to researchers.
It is worth remembering that this will be the first Brazilian phase 3 study on the effects of CBD in the treatment of long Covid. We’re talking about a clinical condition caused by Covid, which remains even after the body beats the virus. Patients continue with the same symptoms, including fatigue, muscle weakness, headache, psychiatric problems, vomiting and diarrhea for up to nine months.
This week, the research was delivered to be filed with the Teaching and Research Committee of the University of São Paulo. “The approval for the start of the clinical study is expected in November, since the issues related to Covid are urgent”, says Verdemed’s CEO, José Bacellar.
Chad-98Weaver, a distinguished author at NewsBulletin247, excels in the craft of article writing. With a keen eye for detail and a penchant for storytelling, Chad delivers informative and engaging content that resonates with readers across various subjects. His contributions are a testament to his dedication and expertise in the field of journalism.
